select a format

Single User License
USD 2000 INR 128580
Site License
USD 4000 INR 257160
Corporate User License
USD 6000 INR 385740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H2 2016

Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H2 2016


  • Products Id :- GMDHC8895IDB
  • |
  • Pages: 53
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H2 2016, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.

Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Influenza A Virus, H7N9 Subtype Infections Overview 7

Therapeutics Development 8

Pipeline Products for Influenza A Virus, H7N9 Subtype Infections-Overview 8

Pipeline Products for Influenza A Virus, H7N9 Subtype Infections-Comparative Analysis 9

Influenza A Virus, H7N9 Subtype Infections-Therapeutics under Development by Companies 10

Influenza A Virus, H7N9 Subtype Infections-Therapeutics under Investigation by Universities/Institutes 11

Influenza A Virus, H7N9 Subtype Infections-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Influenza A Virus, H7N9 Subtype Infections-Products under Development by Companies 14

Influenza A Virus, H7N9 Subtype Infections-Products under Investigation by Universities/Institutes 15

Influenza A Virus, H7N9 Subtype Infections-Companies Involved in Therapeutics Development 16

EpiVax Inc 16

Fab'entech 17

Genentech Inc 18

GlaxoSmithKline Plc 19

Medigen Vaccine Biologics Corp 20

NanoViricides Inc 21

Visterra Inc 22

Vivaldi Biosciences Inc 23

Influenza A Virus, H7N9 Subtype Infections-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

AT-501-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

FBF-002-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

GSK-3206640A-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

GSK-3206641A-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

influenza [strain A/H7N9] (monovalent) vaccine-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

influenza [strain A/H7N9] vaccine-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

influenza [strain A/H7N9] vaccine-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Monoclonal Antibody to Inhibit Hemagglutinin for Influenzavirus A Infections-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

NVINF-1-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

NVINF-2-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

VIS-410-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Figures

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2016 8

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections-Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Targets, H2 2016 25

Number of Products by Stage and Targets, H2 2016 25

Number of Products by Mechanism of Actions, H2 2016 27

Number of Products by Stage and Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Molecule Types, H2 2016 31

List of Tables

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2016 8

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections-Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Influenza A Virus, H7N9 Subtype Infections-Pipeline by EpiVax Inc, H2 2016 16

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Fab'entech, H2 2016 17

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Genentech Inc, H2 2016 18

Influenza A Virus, H7N9 Subtype Infections-Pipeline by GlaxoSmithKline Plc, H2 2016 19

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Medigen Vaccine Biologics Corp, H2 2016 20

Influenza A Virus, H7N9 Subtype Infections-Pipeline by NanoViricides Inc, H2 2016 21

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Visterra Inc, H2 2016 22

Influenza A Virus, H7N9 Subtype Infections-Pipeline by Vivaldi Biosciences Inc, H2 2016 23

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

EpiVax Inc, Fab'entech, Genentech Inc, GlaxoSmithKline Plc, Medigen Vaccine Biologics Corp, NanoViricides Inc, Visterra Inc, Vivaldi Biosciences Inc

Influenza A Virus, H7N9 Subtype Infections Therapeutic Products under Development, Key Players in Influenza A Virus, H7N9 Subtype Infections Therapeutics, Influenza A Virus, H7N9 Subtype Infections Pipeline Overview, Influenza A Virus, H7N9 Subtype Infections Pipeline, Influenza A Virus, H7N9 Subtype Infections Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com